# CodeBreak 300 (NCT05198934)

> Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05198934
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Amgen
- Conditions: Colorectal Cancer (CRC)
- Interventions: Sotorasib; Panitumumab; Trifluridine and Tipiracil; Regorafenib
- Enrollment: 160
- Primary outcome: Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 54
- YouTube: 35
- Podcasts: 28
- Bluesky threads: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=codebreak-300-nct05198934

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05198934", "email": "<work email>"}; the inbox owner confirms by the emailed link.